NanoViricides to Present at NIBA Conference and Announces Completion of NV-387 Production

NanoViricides, Inc., a leading clinical stage company in antiviral drug development, announced its participation at the NIBA's 152nd Investment Conference in Fort Lauderdale, Florida. The company disclosed that it has completed the production of NV-387 Oral Gummies, an antiviral drug ready for Phase II clinical trials once site readiness is achieved.

Anil R. Diwan, the President and Executive Chairman, will present at the conference, providing insights into the drug's potential to treat multiple viral infections, including RSV, Influenza, and Coronaviruses. NV-387 has successfully passed Phase I trials, demonstrating safety and tolerability in human subjects.

Moreover, NV-387 is set to enter Phase II trials for Monkeypox treatment, approved by the DRC regulatory agency, ACOREP. NanoViricides' innovative approach mimics host cells to target viruses effectively, positioning NV-387 as a promising broad-spectrum antiviral solution.